Pap Smear Guidelines: Family Planning Update 2008 Part Two

Produced by the Alabama Department of Public Health
Video Communications and Distance Learning Division

Faculty

Seshu P. Sarma, MD, FAAP
Emory University Regional
Training Center
Atlanta, Georgia

Objectives

- Discuss pap smear reporting
- Describe the Bethesda system 2006
- Discuss management of unsatisfactory smears and smears with no T zone component

Objectives

- Discuss management strategies for various squamous and gladular cell abnormalities
- Discuss treatment modalities for CIN

Cervical Cancer

- Pap smear screening resulted in dramatic reduction in cervical cancer
- The value of accurate screening can be reduced by loss to follow-up or under-treatment of significant lesions

Pap Smear Reporting

- Pap system of reporting
  - Bethesda 1988 system
  - Bethesda 1991 system
  - Bethesda 2001 system
  - Bethesda 2006 system

Pap Reporting

- Class 1
  - Normal
- Class 2
  - Atypia, inflammation, reactive change
- Class 3
  - Dysplasia
    - Mild, moderate and severe
- Class 4
  - Carcinoma in situ
- Class 5
  - Invasive cancer

WHO Reporting

- CIN 1
  - Mild dysplasia
- CIN 2
  - Moderate dysplasia
- CIN 3
  - Severe dysplasia
  - Carcinoma in situ

Bethesda System

- Bethesda 1988
- Bethesda 2001
- Bethesda 2006

Bethesda 2006

- 146 experts
- 29 organizations
- Met September 18-19, 2006 in Bethesda, MD
- Developed revised, evidence based consensus guidelines for management of abnormal pap smears

Bethesda 2006

- ASCUS
- LGSIL
  - Management unchanged for the above 2 categories except for adolescents
  - Cytologic follow-up for 2 years approved for adolescents

Bethesda 2006

- Recommendations for HSIL and AGC underwent only minor changes
- More emphasis placed on immediate screen and treat for HSIL lesions

Bethesda 2006

- HPV testing was incorporated into the management of AGC after initial evaluation with colposcopy and endometrial sampling

Bethesda 2006

- The 2004 interim guidance for HPV testing as a adjunct to cervical cytology for screening in women 30 years of age or older was formally approved

Adequate Specimen

- Conventional Smear:
  - 8,000-12,000 well visualized cells should be seen
- Liquid-based Pap:
  - 5,000 well visualized cells should be seen
  - Epithelial cells may be obscured by inflammation
  - If >75% of cells are obscured, it is considered unsatisfactory

Adequacy of Specimen

- Satisfactory specimen contains
  - 10 well preserved endocervical cells

    or
  - 10 squamous metaplastic cells

Transformation Zone Not Present

- If Pap is otherwise normal, no higher risk of subsequent detection of high grade SIL
- Most women without an endocervical or transformation zone component can be re-screened in 12 months

No T Zone Components

- Repeat testing is recommended for women at higher risk of neoplasia such as:
  - Immunocompromised
  - HPV +
  - previous abnormal pap smears
  - Inability to visualize the cervix
  - Insufficient previous screening

Unsatisfactory Pap Smears

- Pap smears that are unsatisfactory need to be repeated in 2-4 months
- If three consecutive specimens are unsatisfactory, colposcopy is recommended
  - Histologic abnormalities were found in 16% of this population

Abnormal Pap Smears

- 50-60 million pap tests per year in US
- 3.5 million are classified as abnormal and require some form of medical follow-up
- 10,000 new cases of cervical cancer seen each year in the US
- 4,000 deaths from cervical cancer

Abnormal Pap and Cervical Cancer

- Determining which women with abnormal Pap tests are at risk of significant cervical disease and treating them presents a:
  - major public health challenge
  - multibillion dollar cost to our healthcare system

Inconclusive Pap Smears

- Almost 2 million Pap smears each year are classified as "inconclusive"
  - ASC-US, ASC-H and LSIL
- Most of them have no detectable problem
- Less than one fifth of these women have a significant precancerous lesion

Inconclusive Pap Smears

- Although these changes are mild, they may result in:
  - Anxiety
  - Unnecessary medical procedures
  - Extra costs to healthcare system

Abnormal Pap Smears

- Effective cervical cancer prevention requires
  - Recognition and treatment of the precursors of invasive cancer
- The 2001 Bethesda System of nomenclature describes the categories of epithelial cell abnormalities seen on pap smears

2001 Bethesda System

- Squamous Cell:
  - Atypical Sqaumous Cells
    - ASC-US (undetermined significance)
    - ASC-H (can not exclude HSIL)
  - Low-grade squamous intraepithelial lesions
    - Mild dysplasia
    - HPV changes

2001 Bethesda System

- Squamous Cell:
  - High-grade squamous intraepithelial lesions
    - Moderate and severe dysplasia and carcinoma-in-situ (CIN II and CIN III)
  - Squamous cell carcinoma

2001 Bethesda System

- Glandular Cell:
  - Atypical glandular cells (AGC)
    - Endocervical
    - Endometrial
    - Not otherwise specified (NOS)

2001 Bethesda System

- Glandular Cell:
  - Atypical glandular cells
    - Favor neoplasia
      - Specify endocervical
      - Not otherwise specified (NOS)
  - Endocervical adnocarcinoma in situ (AIS)
  - Adenocarcinoma

Precancerous Precursors

- CIN 2, CIN 3, adeno-carcinoma in situ (AIS) are collectively referred to as CIN2/3+
- Cancer precursors include:
  - CIN 3, AIS and to a lesser extent CIN 2

HPV and Abnormal Paps

- The presence of HPV is a marker for the risk of diagnosis of CIN2/3+
- Only 1 in 10 to 1 in 30 HPV infections are associated with abnormal cervical cytology
- Even a smaller proportion are associated with CIN2/3/+

HPV

- Among women with negative cytology and a positive HPV test result, only 15% will have abnormal cytology results within 5 years

HPV

- HPV can express as CIN within months after infection
- However, the time course from CIN 3 to invasive cancer averages between 8.1 and 12.6 years

CIN Regression

- Regression for CIN
  - 60% for CIN 1 and 40% for CIN 2

CIN 1

- CIN 1 is the histologic appearance of cells producing HPV
- The goals of cervical cancer screening:
  - Not to prevent CIN
  - But to prevent and treat
    - Early invasive cervical cancer
    - Reduce mortality

Management of Abnormal Pap

- Atypical Squamous Cells:
- The risk of cancer and CIN 2/3+ is low
  - 0.1-0.2% for cancer
  - 6.4-11.9% for CIN2/3+

Atypical Squamous Cells

- Options include:
  - Immediate colposcopy
    - Provides rapid diagnosis but expensive
  - HPV DNA testing triage
  - Repeat cytology at 6 and 12 months

HPV Testing

- Hybrid Capture DNA 2 assay for 13 oncogenic HPBV sub types
- Performed on the liquid based pap specimen
- Usually done within 3 weeks of obtaining the specimen

ASCUS (HPV+) in Adolescents

- The risk of invasive cancer approaches zero in adolescents
- HPV infections are common and self limiting in adolescents
- Colposcopic evaluation is not necessary
- Can be monitored with pap smears at 6 and 12 months

Adolescents

- Recommendations are similar for ASC and LSIL in adolescent girls
- LSIL represents HPV infection and most adolescents clear HPV and LSIL
- Follow-up Pap at 6 and 12 months is adequate

ASCUS and LSIL in Adolescents

- Follow-up with cytology or HPV for up to 2 years is reasonable according to Bethesda 2006 guidelines

LSIL

- More frequent in younger populations with larger number of recent partners
- Represents the appearance of cells that are actively engaged in HPV replication
- HPV testing is of limited value

LSIL

- The risk of CIN 2/3+ at initial colposcopy following an LSIL is between 15% and 30%
- Colposcopy is recommended for these women
- For adolescents with LSIL, follow-up with Pap at 6 and 12 months is reasonable

LSIL in Adolescents

- Follow-up at 6 and 12 months
  - Those with HSIL need colposcopy
- Follow-up at 24 months
  - Those with ASCUS or greater need colposcopy
    - Bethesda 2006 guidelines

LSIL in Postmenopausal Women

- Options include:
  - Reflex HPV DNA testing
  - Repeat cytology at 6 and 12 months
  - Colposcopy
    - 2006 Bethesda guidelines

ASC-H

- Atypical squamous cells-cannot exclude HSIL (ASC-H);
  - Includes 5-10% of ASC Pap smears
  - CIN2/3+ seen in 24-94% of such cases
  - Immediate colposcopic intervention is necessary
  - HPV testing is not cost effective

HSIL

- Among women with HSIL cytology results:
  - CIN 2 and CIN 3 have been reported in 70% or more cases
  - Invasive cancer is seen in 1-2% of cases
  - Colposcopy with endocervical evaluation should be done
  - Entire vagina should be examined
  - See and treat approach can be followed if lesion seen

AGC

- Atypical Glandular Cells:
  - Histological correlation:
  - 9-38% of women with AGC have significant neoplasia
  - 3-17% have cancer
  - CIN is the most common lesion associated with AGC

AGC

- Source of the lesion
  - Cervix
  - Endocervix
  - Endometrium

AGC

- Evaluation includes:
  - Colposcopy
  - Endocervical curettage
  - Endometrial sampling
    - With abnormal endometrial cells
    - Women >35 years of age
    - Younger women with abnormal bleeding, morbid obesity and oligomenorrhea

AGC

- When evaluation is negative and histology is negative, follow-up includes:
  - AGC favor neoplasia: excision is warranted
    - Cold knife cone is a good choice
  - AGC and AGC NOS
    - Pap and ECC every 6 months until 4 consecutive negative smears are obtained

How Should CIN 1 Be Managed?

- Depends on the preferences of the
  - Physician and the patient
  - For most young women, observation seems appropriate
  - Follow-up with pap smear every 6 months X 2
    - Colposcopy for an ASC or higher
    - or a positive HPV at 12 months

CIN 2 and 3

- CIN 2 and 3 are recognized potential cancer precursors
  - Although CIN2 is associated with significant spontaneous regression
  - 40% of CIN 2 cases regress over 2 years
- Immediate treatment of CIN2 and CIN 3 with excision or ablation is recommended in non-pregnant patients

CIN 2 in Adolescents

- Care of the adolescent with CIN 2 may be individualized
- Treatment may be deferred
- Close follow-up with pap and colposcopy may be adequate

Management of AIS

- Cold-knife conization is recommended
  - To preserve specimen orientation
  - Permit optimal interpretation of histology and margin status
- LEEP is not recommended

Hysterectomy for CIN 2/3+

- Hysterectomy is not the initial treatment of choice for
  - CIN 2 or 3
  - May be considered fo persistent or recurrent CIN 2 or 3

Abnormal Pap in Pregnancy

- ASC or LSIL:
  - Colposcopy during pregnancy or at 6-12 weeks postpartum
- ASC-H
  - Immediate colposcopy

Abnormal Pap in Pregnancy

- HSIL
  - Immediate colposcopy
- AGC
  - Immediate colposcopy
  - No endocervical sampling is done during pregnancy

Pregnancy

- CIN is not treated in pregnancy
- Excision should be considered
  - If lesion is suspicious for invasive CA
- Repeat colposcopic evaluation is done during pregnancy as needed
- Reassessment by colposcopy
  - 6-12 weeks postpartum

Treatment Modalities for CIN

- Cryotherapy
- Laser ablation
- LEEP
- Cold knife cone biopsy
  - Cryotherapy or laser ablation are done only when endocervical pathology is ruled out

See and Treat Approach

- During colposcopic evaluation, when significant abnormality is found, LEEP is performed to both evaluate and treat the precancerous condition

Management of Cervical Disease

- Diagnostic Procedures:
  - HPV DNA testing
  - Colposcopy
  - LEEP (both diagnostic and therapeutic)
  - Cone biopsy (both diagnostic and therapeutic)

Hybrid Capture DNA Assay

- Hybrid Capture DNA 2 assay
- Designed to detect 13 high-risk HPV subtypes (16,18,31,33,35,39,45,51,52,56,58,59,68)

HPV DNA (High Risk) Testing

- Potential indications:
  - Triage of patients with ASCUS
  - Surveillance of HSIL
  - Combination Pap/DNA testing

Self Collected HPV DNA

- Studies suggest that self-collected specimens for HPV testing may offer
  - A means to increase screening
  - Primary screening of older women

Founier Self Collection Device

Colposcopy

- Evaluation of the
  - Cervix and vagina
  - Vulva
- With 10 – 25 times magnification
- Acetic acid 3-6 % solution used
- Cervix and vagina are evaluated before and after acetic acid is applied

Colposcopy

- Pap smear is a screening test
- Colposcopy is the diagnostic test to confirm the disease process



Colposcopy

- Colposcopy is performed when:
  - The pap smear is abnormal
  - The cervix looks abnormal
  - Women are exposed to DES in utero

Treatment

- Cryotherapy
- Laser
- Cone biopsy
- LEEP (Loop Electrical Excision Procedure)

Treatment of Cervical Disease

- Treatment of the precancerous disease depends on the
  - Severity of the disease
    - Mild, moderate or sever dysplasia or CIS
  - Involvement of the endocervical canal
  - On the age of the patient such as an adolescent

Cryotherapy

- Destruction of abnormal tissue by freezing
- Cryotherapy destroys normal tissue along with the abnormal tissue

Cryosurgery

Cryo Tip

Cone Biopsy

- Cone biopsy is an extensive form of cervical biopsy
- A wedge shaped tissue is removed from the cervix and examined under a microscope

Cone Biopsy

- Cone biopsy removes abnormal tissue that is high in the cervical canal
- A small amount of normal tissue around the abnormal tissue is removed so that a margin free of abnormal cell is left in the cervix

Cold Knife Cone Biopsy

Cold Knife Cone Biopsy

Cold Knife Cone Biopsy

Cold Knife Cone Biopsy

Cone Biopsy

- Cone biopsy can be done using
  - A surgical knife (cold knife cone)
  - A carbon dioxide laser
  - LEEP (Loop Electrical Excision Procedure)

LEEP/LLETZ

- Loop Electro-surgical Excision Procedure, also know as large loop excision of the transformation zone is a technique used for treatment and diagnosis of cervical dysplasia.

LEEP



LEEP

LEEP



LEEP

LEEP

- LEEP
  - Performed as an outpatient technique at the gynecologist's office except under special circumstances
- The cervix is numbed, and a portion of the cervix is removed with a thin wire loop carrying a small electrical current
- The tissue is then sent for pathologic evaluation

Counseling

- Emphasize practicing safer sex in the future
- Encourage involvement of partners in the discussion
- Provide culturally sensitive and appropriate educational materials that are helpful
- Give them opportunity to return and discuss the information at a later time

Cervical Cancer

- HPV is the primary cause of cervical cancer
- In most cases, the HPV is harmless and causes no symptoms
- The majority of women with HPV will not develop cervical cancer
- Cervical cancer is completely preventable if precancerous changes are detected and removed from the cervix

References

- The HPV DNA virus hybrid capture assay:
- What is it-and where do we go from here? www.mlo-online.com (March 2003)
- Cervical cancer: prevention, diagnosis, and therapeutics:www.cancer.org
- Human Papillomaviruses: applications, caveats and prevention: The journal of Reproductive Medicine: Volume 47, No. 7/July 2002

References

- **ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecoogists Number 66, September 2005**
- **Bethesda 2006 guidelines**